MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) has obtained US Food and Drug Administration (FDA) marketing approval for its ActiveCare + Dx non-invasive device for treating deep vein thrombosis. The company will begin marketing the system in 2012.
MCS says that the system, a development of its flagship ActiveCare + SFT device, is the only device on the market that combines simultaneous venous obstruction prevention and detection during prophylactic therapy. The company added that, currently, there is a 5-6% risk of developing deep vein thrombosis in patients who receive medication and/or other therapy after orthopedic surgery, but there no treatments or technologies that can alert on prevention failure.
MCS says that the ActiveCare + Dx system will allow quicker identification of these patients and earlier treatment to begin, immediately after the presence of a blood clot is verified. Early diagnosis should greatly reduce severe complications, such as potentially lethal pulmonary embolisms.
A large clinical trial in the US found that use of ActiveCare + SFT was more effective than the deep vein thrombosis drug Lovenox on patients after hip replacement surgery. MCS says that the ActiveCare + Dx system has an advantage over medication by providing early diagnosis in patients where preventative care has failed.
MCS's share price rose 2% by midday to NIS 4.02, giving a market cap of NIS 163 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011